Kalaris Therapeutics, Inc.

KLRS · Nasdaq · SIC 2836: Biological Products, (No Diagnostic Substances)
103
SEC Filings

Business Summary

PART I . Overview We are a clinical stage biopharmaceutical company dedicated to the development and commercialization of treatments for prevalent retinal diseases with major unmet medical needs. We are developing TH103, a novel, clinical stage anti-vascular endothelial growth factor (VEGF) drug, specifically engineered to achieve extended intraocular retention with enhanced VEGF inhibition in patients with exudative and/or neovascular retinal diseases. TH103 is a fully humanized recombinant fus...

Next Earnings

Q2 FY2026 — expected 2026-08-08

Key Facts from Earnings Calls

TypeSubjectDetailQuarter
topic_mentionKLRSdiscussed_in_filing Cybersecurity
topic_mentionKLRSdiscussed_in_filing Cybersecurity
topic_mentionKLRSdiscussed_in_filing Healthcare & Bio
topic_mentionKLRSdiscussed_in_filing Healthcare & Bio

Annual Reports (10-K)

FiledPeriodAccessionSourceFull Text
2026-03-172025-12-310001193125-26-110659EDGAR126K words
2025-03-072024-12-310000950170-25-035143EDGAR—
2024-03-152023-12-310000950170-24-031879EDGAR—
2023-02-152022-12-310000950170-23-002830EDGAR—
2022-02-102021-12-310000950170-22-001075EDGAR—
2021-02-122020-12-310001564590-21-005652EDGAR—

Quarterly Reports (10-Q)

FiledPeriodAccessionSourceFull Text
2025-11-122025-09-300001193125-25-277464EDGAR85K words
2025-08-132025-06-300000950170-25-107979EDGAR—
2025-05-142025-03-310000950170-25-071339EDGAR—
2024-11-122024-09-300000950170-24-125295EDGAR—
2024-08-092024-06-300000950170-24-094380EDGAR—
2024-05-132024-03-310000950170-24-058607EDGAR—
2023-11-022023-09-300000950170-23-058145EDGAR—
2023-08-032023-06-300000950170-23-037926EDGAR—
2023-05-042023-03-310000950170-23-017814EDGAR—
2022-11-032022-09-300000950170-22-021829EDGAR—
2022-08-042022-06-300000950170-22-014726EDGAR—
2022-05-052022-03-310000950170-22-007792EDGAR—

Recent Current Reports (8-K)

FiledAccessionSourceFull Text
2026-03-170001193125-26-109437EDGAR2K words
2026-03-090001193125-26-097548EDGAR—
2025-12-180001193125-25-323706EDGAR—
2025-12-170001193125-25-322950EDGAR—
2025-11-120001193125-25-276060EDGAR—
2025-11-030001193125-25-261697EDGAR—
2025-08-130001193125-25-179466EDGAR—
2025-08-130001193125-25-179464EDGAR—
2025-06-200001193125-25-143202EDGAR—
2025-05-140001193125-25-119408EDGAR—

103 total filings indexed. 75 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR

Sector Peers

FDMT — 4D Molecular Therapeutics, Inc. APTN — ADAPTIN BIO, INC. ADMA — ADMA BIOLOGICS, INC. AGEN — AGENUS INC AIM — AIM ImmunoTech Inc. AMGN — AMGEN INC AVXL — ANAVEX LIFE SCIENCES CORP. ABPO — Abpro Holdings, Inc.

Company Identity

CIK0001754068
TickerKLRS
ExchangeNasdaq
SIC2836: Biological Products, (No Diagnostic Substances)
IncorporatedDE

Get More Data

This is the free public profile. For structured JSON with full provenance chain, use the API:

JSON Profile Stock Quote AI Readiness Report
Origin Provenance
page leaf: 19e914a710d8348ec68e42f64d030529c78e2d3450bade2c72fe14a6fb92a03a
parent: 81e840460a23ba2bb2ce177939181ed7ed8da1153bc832bc3f8100c1fa0c15fb
content hash: a0f800846d3b5f4ef331c870e532a060bb283a21c0d22ca9d88e7441ec8f5bb8
signed: 2026-04-13T04:45:53.784Z
sources: 18 verified data leaves
chain: SEC.gov PEM → origin.rootz.global extraction → this page
verify: sha256(content_hash + parent + timestamp) = leaf